<DOC>
	<DOCNO>NCT00000138</DOCNO>
	<brief_summary>To evaluate efficacy topical corticosteroid treat herpes simplex stromal keratitis conjunction topical trifluridine . To evaluate efficacy oral acyclovir treat herpes simplex stromal keratitis patient receive concomitant topical corticosteroid trifluridine . To evaluate efficacy oral acyclovir treat herpes simplex iridocyclitis conjunction treatment topical corticosteroid trifluridine .</brief_summary>
	<brief_title>Herpetic Eye Disease Study ( HEDS ) I</brief_title>
	<detailed_description>Herpes simplex keratitis lead cause corneal opacification United States , industrialized country , develop nation throughout world . An estimated 450,000 people United States develop recurrent episode disease 46,000 episode HSV eye infection every year . Herpetic eye disease common infectious cause corneal blindness country . Despite availability antiviral agent effective treat herpes simplex epithelial keratitis , inflammation corneal connective tissue iris lead corneal scar visual impairment develop many patient . Prior HEDS-I trial , role topical corticosteroid management HSV stromal keratitis uncertain ; animal human study suggest benefit treatment whereas others suggest harm . The value add oral antiviral agent treatment topical corticosteroid topical antiviral also unknown . The HEDS-I trial develop assess efficacy topical corticosteroid oral acyclovir treat HSV stromal keratitis iridocyclitis . HEDS-I consist three randomize , placebo-controlled trial . The organizational structure consist data coordinate center eight clinical center . All patient receive topical antiviral trifluridine prophylaxis recurrence HSV epithelial ulceration . Patients evaluate weekly 10 week , every week week 16 , 6 month . The primary outcome time development preset criterion treatment failure 16-week period examination . Protocol-specific description three trial follow . Herpes Stromal Keratitis , Not Steroid Trial ( HEDS-SKN ) : Patients active HSV stromal keratitis use topical corticosteroid precede 10 day randomize treatment topical prednisolone phosphate drop topical placebo drop . A treatment schedule , start 8 drop day 1 percent prednisolone phosphate 7 day , progressively decrease 10 week way patient receive 1 drop per day 1/8 percent prednisolone last 3 week treatment . Placebo drop give schedule . Herpes Stromal Keratitis , Steroid Treatment ( HEDS-SKS ) : Patients active HSV stromal keratitis already treat topical corticosteroid randomize either oral treatment 200 mg acyclovir capsule ( 400 mg five time daily ) 10 week identical dose placebo capsule . Patients also receive topical prednisolone phosphate dosage schedule describe SKN trial . Herpes Simplex Virus Iridocyclitis , Receiving Topical Steroids ( HEDS-IRT ) : Patients active HSV iridocyclitis randomize either oral treatment 200 mg acyclovir capsule ( 400 mg five time daily ) 10 week identical dose placebo capsule . Patients also receive topical prednisolone phosphate dosage schedule describe SKN trial .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Keratitis</mesh_term>
	<mesh_term>Keratitis , Herpetic</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<criteria>Eligibility criterion common three protocol include age 12 year old , active HSV epithelial keratitis , prior keratoplasty involve eye , pregnant . Protocolspecific criterion note description .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Herpes Simplex Stromal Keratitis</keyword>
</DOC>